413 related articles for article (PubMed ID: 31389386)
1. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
[TBL] [Abstract][Full Text] [Related]
2. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of tumor-infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis.
Li X; Tan Q; Li H; Yang X
J Surg Oncol; 2021 Jan; 123(1):89-95. PubMed ID: 33047336
[TBL] [Abstract][Full Text] [Related]
4. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
[TBL] [Abstract][Full Text] [Related]
5. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis.
Park S; Park JM; Cho JH; Park HS; Kim SI; Park BW
Ann Surg Oncol; 2013 Sep; 20(9):2858-65. PubMed ID: 23645483
[TBL] [Abstract][Full Text] [Related]
6. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
7. Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients.
Canavese G; Tinterri C; Carli F; Garrone E; Spinaci S; Della Valle A; Barbieri E; Marrazzo E; Bruzzi P; Dozin B
Eur J Surg Oncol; 2021 Aug; 47(8):1920-1927. PubMed ID: 33972144
[TBL] [Abstract][Full Text] [Related]
8. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
[TBL] [Abstract][Full Text] [Related]
9. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study.
Kim SH; Jung KH; Kim TY; Im SA; Choi IS; Chae YS; Baek SK; Kang SY; Park S; Park IH; Lee KS; Choi YJ; Lee S; Sohn JH; Park YH; Im YH; Ahn JH; Kim SB; Kim JH
Cancer Res Treat; 2016 Oct; 48(4):1373-1381. PubMed ID: 27034147
[TBL] [Abstract][Full Text] [Related]
11. The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer.
Namura M; Tsunoda H; Kobayashi D; Enokido K; Yoshida A; Watanabe T; Suzuki K; Nakamura S; Yamauchi H; Hayashi N
Clin Breast Cancer; 2019 Aug; 19(4):278-285. PubMed ID: 30975473
[TBL] [Abstract][Full Text] [Related]
12. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy.
Chun JW; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
Sci Rep; 2021 Apr; 11(1):9056. PubMed ID: 33907236
[TBL] [Abstract][Full Text] [Related]
13. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
14. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
15. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Lymph Node Ratio in Breast Cancer Patients with Adequate Pathologic Evidence After Neoadjuvant Chemotherapy.
Ai X; Liao X; Wang M; Hu Y; Li J; Zhang Y; Tang P; Jiang J
Med Sci Monit; 2020 Apr; 26():e922420. PubMed ID: 32348295
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
[TBL] [Abstract][Full Text] [Related]
18. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782
[TBL] [Abstract][Full Text] [Related]
20. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status.
Zetterlund L; Celebioglu F; Hatschek T; Frisell J; de Boniface J
Br J Surg; 2021 May; 108(5):583-589. PubMed ID: 34043772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]